Brilacidin, the CTIX antibiotic is just getting ready for a phase III trial and won't be on the market until that trial is completed successfully. CTIX most likely won't get their major payday until Brilacidin is on the market and revenue producing.
Major pharma companies won't pay the premium until the risk is out. And, the risk won't be out until the phase III for Brilacidin is successfully completed. It's that simple. Be happy you are in at the $3 price range. The probability of a successful phase III is high if we get solid bottom line results on the phase IIb.
Plus, by the time the phase III Brilacidin results are in we'll also have a good idea where things stand with Kevetrin and Prurisol.
I'm holding more than I should be based on my trading rules, but, I can't find a better bet.
In Reply to 'shenanigan'
Let's end the nonsense. If a r company with a inferior product is worth 8 Billion and just got a MAJOR payday, WHY is CTIX at 3 $ as share
News 
Market Data 
Discover 
